Marin Daniele, Iannaccone Riccardo, Laghi Andrea, Catalano Carlo, Murakami Takamichi, Hori Masatoshi, Kim Tonsok, Passariello Roberto
Department of Radiological Sciences, University of Rome La Sapienza, Rome, Italy.
J Magn Reson Imaging. 2007 Apr;25(4):775-82. doi: 10.1002/jmri.20885.
To intraindividually compare the enhancement pattern of focal nodular hyperplasia (FNH) after dynamic administration of two bolus-injectable liver-specific MR contrast agents, ferucarbotran and gadobenate dimeglumine.
A total of 19 patients with 24 FNHs underwent gadobenate dimeglumine- and ferucarbotran-enhanced MRI during the hepatic arterial-dominant phase (HAP; 25 seconds), the portal-venous phase (PVP; 60 seconds), and the equilibrium phase (EP; 180 seconds). Hepatospecific phases were acquired on T1-weighted images 120 minutes after gadobenate dimeglumine administration, and on T2-weighted images 10 minutes after ferucarbotran administration. Lesion enhancement was independently analyzed by two observers. The kappa statistic was determined to evaluate the agreement between the enhancement patterns of the lesions.
On gadobenate dimeglumine-enhanced MR images during HAP, PVP, and EP, FNHs were: hyperintense (24/20/13); isointense (0/4/11); and hypointense (0/0/0). On ferucarbotran-enhanced MR images during HAP, PVP, and EP, FNHs were: hyperintense (2/0/0); isointense (16/9/14); and hypointense (6/15/10). Overall, poor agreement between both contrast agents was observed. During the hepatospecific phases, most (20/24; 83%) FNHs showed a typical enhancement pattern during the delayed hepatospecific phase.
The dynamic enhancement pattern of FNHs is significantly different between gadobenate dimeglumine- and ferucarbotran-enhanced MRI. With respect to hepatospecific phase, the majority of FNHs showed a typical behavior on both contrast agents.
在个体内比较两种团注式肝脏特异性磁共振造影剂（ ferucarbotran和钆贝葡胺）动态给药后局灶性结节性增生（FNH）的强化模式。
19例患有24个FNH的患者在肝动脉主导期（HAP；25秒）、门静脉期（PVP；60秒）和平衡期（EP；180秒）接受了钆贝葡胺和ferucarbotran增强MRI检查。在注射钆贝葡胺120分钟后于T1加权图像上采集肝脏特异性期图像，在注射ferucarbotran 10分钟后于T2加权图像上采集肝脏特异性期图像。两名观察者独立分析病变强化情况。采用kappa统计量评估病变强化模式之间的一致性。
在钆贝葡胺增强的MR图像上，HAP、PVP和EP期FNH的表现分别为：高信号（24/20/13）；等信号（0/4/11）；低信号（0/0/0）。在ferucarbotran增强的MR图像上，HAP、PVP和EP期FNH的表现分别为：高信号（2/0/0）；等信号（16/9/14）；低信号（6/15/10）。总体而言，观察到两种造影剂之间的一致性较差。在肝脏特异性期，大多数（20/24；83%）FNH在延迟肝脏特异性期表现出典型的强化模式。
钆贝葡胺和ferucarbotran增强MRI检查中FNH的动态强化模式存在显著差异。在肝脏特异性期方面，大多数FNH在两种造影剂检查中均表现出典型特征。
